methyl 2,3,5-tris-O-(2,4-dichlorobenzyl)-α-D-ribofuranoside | 1312805-10-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: methyl 2,3,5-tris-O-(2,4-dichlorobenzyl)-α-D-ribofuranoside
• 英文别名: (2R,3R,4R,5S)-3,4-bis[(2,4-dichlorophenyl)methoxy]-2-[(2,4-dichlorophenyl)methoxymethyl]-5-methoxy-tetrahydrofuran；(2R,3R,4R,5S)-3,4-bis[(2,4-dichlorophenyl)methoxy]-2-[(2,4-dichlorophenyl)methoxymethyl]-5-methoxyoxolane
• CAS: 1312805-10-9
• 化学式: C₂₇H₂₄Cl₆O₅
• 分子量: 641.203
• InChiKey: QTZFDEIPDKCKBR-CWTOASCOSA-N

物化性质

• 沸点：
  667.9±55.0 °C(Predicted)
• 密度：
  1.47±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  7.9
• 重原子数：
  38
• 可旋转键数：
  11
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  46.2
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  卡培他滨杂质25 在 硫酸 、 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 、 mineral oil 为溶剂， 反应 28.0h， 生成 methyl 2,3,5-tris-O-(2,4-dichlorobenzyl)-α-D-ribofuranoside 、 methyl 2,3,5-tris-O-(2,4-dichlorobenzyl)-β-D-ribofuranoside
  参考文献：
  名称：

  Discovery of 2′-α-C-Methyl-2′-β-C-fluorouridine Phosphoramidate Prodrugs as Inhibitors of Hepatitis C Virus

  摘要：

  2'-alpha-C-Methyl-2'-beta-C-fluorouridine and its phosphoramidate prodrugs were synthesized and evaluated for their inhibitory activity against HCV. The structure-activity relationship analysis of the phosphoramidate moiety found that 17m, 17q, and 17r exhibit potent activities against HCV, with EC50 values of 1.82 +/- 0.19, 0.88 +/- 0.12, and 2.24 +/- 0.22 mu M, respectively. The docking study revealed that the recognition of the 2'-beta-F by Arg158, 3'-OH by N291, and the Watson Crick pairing with the template allowed 23 to form the in-line conformation necessary for its incorporation into the viral RNA chain.

  DOI：

  10.1021/acsmedchemlett.6b00270

文献信息

• Nucleoside compounds for treating viral infections
  申请人：Roberts D. Christopher

  公开号：US20050090463A1

  公开（公告）日：2005-04-28

  Disclosed are compounds, compositions and methods for treating viral infections caused by a flaviviridae family virus, such as hepatitis C virus.

  揭示了用于治疗由黄病毒科病毒引起的病毒感染的化合物、组合物和方法，例如丙型肝炎病毒。
• 5-nitro-nucleoside compounds for treating viral infections
  申请人：Keicher D. Jesse

  公开号：US20060111311A1

  公开（公告）日：2006-05-25

  Disclosed are compounds, compositions and methods for treating viral infections caused by a flaviviridae family virus, such as hepatitis C virus.

  揭示了用于治疗由黄病毒科病毒引起的病毒感染的化合物、组合物和方法，例如丙型肝炎病毒。
• Nucleoside derivatives for treating hepatitis C virus infection
  申请人：Roberts D. Christopher

  公开号：US20050119200A1

  公开（公告）日：2005-06-02

  Disclosed are compounds, compositions and methods for treating viral infections caused by a flaviviridae family virus, such as hepatitis C virus.

  本发明涉及用于治疗由黄病毒科病毒引起的病毒感染的化合物、组合物和方法，例如治疗丙型肝炎病毒感染。
• Oligonucleotide analogs having modified dimers
  申请人：——

  公开号：US20030181693A1

  公开（公告）日：2003-09-25

  Modified dimers having a ribose sugar moiety in the 5′ nucleoside and a 2′ modified sugar in the 3′ nucleoside are provided. The modified dimers are useful in the preparation of oligonucleotide analogs having enhanced properties compared to native oligonucleotides, including increased nuclease resistance, enhanced binding affinity and improved protein binding.

  提供了具有核糖糖基在5'核苷酸和2'修饰糖在3'核苷酸的改性二聚体。这些改性二聚体在制备寡核苷酸类似物时非常有用，与天然寡核苷酸相比具有增强性能，包括增加核酸酶抵抗力，增强结合亲和力和改善蛋白结合。
• NUCLEOSIDE DERIVATIVES FOR TREATING HEPATITIS C VIRUS INFECTION
  申请人：Roberts Christopher D.

  公开号：US20090036399A1

  公开（公告）日：2009-02-05

  Disclosed are methods for treating viral infections caused by a flaviviridae family virus, such as hepatitis C virus. Such compounds are represented by Formula I as follows: wherein W, W 1 , W 2 , Y, R 1 , Z, Y′ and R are as defined herein.

  本发明揭示了治疗由黄病毒科病毒引起的病毒感染的方法，例如丙型肝炎病毒。这些化合物的公式如下：其中W、W1、W2、Y、R1、Z、Y'和R的定义如下。